Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
HOME > REGULATORY
REGULATORY
- Commentary: 1st Sakigake Drugs Picked via “Comparative Evaluation”, Will All Qualified Products Get Designated in the Future?
October 28, 2015
- Thrombopenia Added to Clinically Significant ADR List for Daklinza, Sunvepra
October 28, 2015
- MHLW Eager to Expedite Commercialization of Sakigake Products: New Bureau Head
October 28, 2015
- Keytruda, Novel Anti-Flu Drug Join Japan’s First Sakigake Designation List
October 28, 2015
- MHLW to Talk with MIC about Local Tax Grants to Deal with Increased Costs of Flu Vaccines: Health Service Bureau Chief
October 28, 2015
- 6 Drugs Get Sakigake Designation for Fast-Track Review
October 27, 2015
- New Chief of MHLW Health Policy Bureau Vows to Balance Generic Push and Innovation
October 27, 2015
- ICH Revamped as Legal Entity, PMDA’s Tominaga Picked as Vice Assembly Chair
October 27, 2015
- MHLW to Implement Steps to Curb Social Security Spending as Needed: New Top Bureaucrat
October 26, 2015
- MHLW Asks Chuikyo to Revise Evaluation for Antipsychotic Therapies in Large Dosages without Adequate Guidance
October 26, 2015
- MHLW Lifts Request for Kaketsuken to Suspend Flu Vaccine Shipment
October 23, 2015
- Chuikyo OKs Expansion of Health Coverage for Investigator-Led Trials
October 22, 2015
- Impact of Z2 Rule to Be Discussed toward FY2016 Reform: MHLW
October 22, 2015
- New MHLW Economic Affairs Chief Visits Logistics Center, Says Distribution Key to Brightening Pharma Sector
October 22, 2015
- MHLW Likely to Announce 5 or So Sakigake Products Next Week
October 22, 2015
- Add Interstitial Pneumonia to Daklinza, Sunvepra Labels: MHLW
October 21, 2015
- MHLW to Show Detailed Steps to Foster Pharma Sector in November
October 21, 2015
- Patent Extension, Patent Linkage Rules in TPP Require No Rule Changes in Japan: MHLW Official
October 20, 2015
- 5 Members to Leave Chuikyo before Full-Fledged Debate Begins for 2016 Reform
October 20, 2015
- Govt to Reduce Stockpiles of Anti-Pandemic Flu Drugs
October 19, 2015
ページ
On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…